- Home
- MSB vs CBIO Comparison
MSB vs CBIO Comparison
Compare MSB & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSB
- CBIO
- Stock Information
- Founded
- MSB 1961
- CBIO 2003
- Country
- MSB United States
- CBIO United States
- Employees
- MSB N/A
- CBIO N/A
- Industry
- MSB Metal Mining
- CBIO
- Sector
- MSB Basic Materials
- CBIO
- Exchange
- MSB Nasdaq
- CBIO Nasdaq
- Market Cap
- MSB 320.9M
- CBIO 308.0M
- IPO Year
- MSB N/A
- CBIO N/A
- Fundamental
- Price
- MSB $30.92
- CBIO $14.29
- Analyst Decision
- MSB
- CBIO Strong Buy
- Analyst Count
- MSB 0
- CBIO 5
- Target Price
- MSB N/A
- CBIO $25.60
- AVG Volume (30 Days)
- MSB 48.2K
- CBIO 98.3K
- Earning Date
- MSB 01-01-0001
- CBIO 07-31-2025
- Dividend Yield
- MSB 22.43%
- CBIO N/A
- EPS Growth
- MSB 335.65
- CBIO N/A
- EPS
- MSB 7.12
- CBIO N/A
- Revenue
- MSB $25,894,592.00
- CBIO N/A
- Revenue This Year
- MSB N/A
- CBIO N/A
- Revenue Next Year
- MSB N/A
- CBIO N/A
- P/E Ratio
- MSB $4.34
- CBIO N/A
- Revenue Growth
- MSB N/A
- CBIO N/A
- 52 Week Low
- MSB $16.55
- CBIO $10.83
- 52 Week High
- MSB $37.00
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- MSB 54.91
- CBIO 52.92
- Support Level
- MSB $30.68
- CBIO $13.50
- Resistance Level
- MSB $33.25
- CBIO $16.00
- Average True Range (ATR)
- MSB 1.06
- CBIO 0.79
- MACD
- MSB -0.24
- CBIO 0.16
- Stochastic Oscillator
- MSB 27.41
- CBIO 39.68
About MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.